CETP activity inhibitors

Details CETP activity inhibitors CETP activity inhibitors

2007-08-03

2009-08-25

Maier, Leigh C (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S630000, C562S840000, C562S867000, C564S142000, C564S154000, C564S191000

Reexamination Certificate

active

07579379

ABSTRACT:
The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I):wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

REFERENCES:
patent: 5041649 (1991-08-01), Bott
patent: 5447830 (1995-09-01), Pawlak et al.
patent: 2000631 (1990-04-01), None
patent: 1201631 (1970-08-01), None
patent: 45-11132 (1970-04-01), None
patent: 47-35786 (1972-12-01), None
patent: 1-278543 (1989-11-01), None
patent: 1-321432 (1989-12-01), None
patent: 2-23338 (1990-01-01), None
patent: 3-226750 (1991-10-01), None
patent: WO 92/03408 (1992-05-01), None
patent: WO 92/03412 (1992-05-01), None
patent: WO 96/09406 (1996-03-01), None
Caplus document 97:72071 abstract of RO 73988 (1981).
Antonova et al.,Dokl. Bulg. Akad. Nauk., 46(1): 71-74 (1993).
Connolly et al.,Biochem. Biophys. Res. Com., 223: 42-47 (1996).
Drozd,Z. Org. Khim., 23(2): 355-365 (1987).
Egan et al.,Adv. Prostaglandin, Thromboxane, and Leukotriene Res., 11: 151-157 (1983).
Hori et al.,Heterocycles, 9(10): 1413-1418 (1978).
Nagarajan et al.,Indian J. Chem., 12(3): 227-235 (1974).
Okamoto et al.,Nature, 406: 203-207 (2000).
Okamoto et al.,Eur. J. Pharmacol, 466: 147-154 (2003).
Simkov et al.,Khim. Getero. Soed., 9: 1192-1195 (1976).
Shinkai et al.,J. Med. Chem., 43: 3566-3572 (2000).
STN Document No. 30:28954 (1936).
STN Document No. 30:28955 (1936).
STN Document No. 31:10413 (1937).
STN Document No. 52:66145 (1958).
STN Document No. 56:13208 (1962).
STN Document No. 57:76819 (1962).
STN Document No. 59:48311 (1963).
STN Document No. 62:3057 (1965).

Affiliated with

Also associated with

Rating

CETP activity inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CETP activity inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CETP activity inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4065079